Health :: The common cold – no cure in sight
What’s the best treatment for a cold? Some say rest and lots of liquids, others say to feed a cold and starve a fever. But what if a person has a cold with a fever? Does medication help?
Virus
Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B – Novartis
Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.
Crohn’s Disease :: Promising results in tough-to-treat crohn’s disease patients
Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.
Alzheimer’s Disease :: Common cold leading to Alzheimer’s disease
Viruses linked to the common cold could be causing memory loss and Alzheimer’s disease in millions of people, new research suggests. Experts suspect that common viruses which infect around one billion people worldwide each year may be invading the central nervous system and damaging the brain. In later life this could lead to symptoms of memory loss and declining mental ability.
Influenza :: Increase Vaccine Supply – Statement by Mike Leavitt, US
The World Health Organization (WHO) has taken a significant step forward in the global effort to prepare for an influenza pandemic by publishing the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. In developing this plan through a consensus of the world?s experts in influenza, immunization, vaccine research, and manufacturing, the WHO has set the world?s sights on the decisive path forward to increase the global capacity to produce pandemic influenza vaccine.
Dengue :: Relief from dengue fever in India
A drop in day temperatures has brought some relief from dengue in north India even as other parts of the country continued to be in the grip of the mosquito-borne viral fever with 199 fresh cases being reported. Across the country, the total number of dengue patients since early September stood at 7,687.
Warts :: Inosiplex in the treatment of cervical condylomata acuminata, genital warts
Conventional treatment for genital warts, which are caused by the human papilloma virus (HPV), typically focuses on the visible lesions, leaving the possibility that latent infection could persist. That can result in transmission of the virus to sexual partners, and the infection could progress to cervical cancer.
Flu :: Asia fighting Bird Flu
“Asia has shown significant progress in preparing to fight the spread of the virus, but more help is needed to support Indonesia, where a majority of the country’s provinces have reported the presence of the disease”, United Nations official, David Nabarro.
Health :: NeuGene Antisense to Alter Drug Metabolism in Humans
AVI BioPharma, Inc. (Nasdaq: AVII), presented data and analysis from four NeuGene? antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in New York. The studies showed that AVI-4557 inhibited the metabolic enzyme cytochrome P450 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs.
HIV :: REYATAZ, atazanavir sulfate for Adults With HIV-1 Infection
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new 300 mg single capsule formulation of REYATAZ? (atazanavir sulfate) for the treatment of HIV-1 infection in adults as part of combination therapy. Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that require SUSTIVA? (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be available in the United States within seven business days.